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Chronic, nonhealing wounds represent a major clin-
ical challenge to practically all disciplines in modern
medicine including dermatology, oncology, surgery,
and hematology. In skin wounds, granulocyte±
macrophage colony stimulating factor (GM-CSF) is
secreted by keratinocytes shortly after injury and
mediates epidermal cell proliferation in an autocrine
manner. Many other cells involved in wound healing
including macrophages, lymphocytes, ®broblasts,
endothelial cells, and dendritic cells synthesize
GM-CSF and/or are targets of this cytokine.
Therefore, GM-CSF is a pleiotropic cytokine evok-
ing complex processes during wound repair. Despite
this complexity and the scarcity of mechanistic
understanding GM-CSF has been employed in trials
of clinical treatment of skin wounds with some suc-
cess. In this study, we evaluated a transgenic mouse
model in order to analyze the effects of an excess of
keratinocyte-derived GM-CSF on excisional wound
healing in the skin. Transgenic mice constitutively
overexpressing GM-CSF in the basal layer of the
epidermis displayed accelerated reepithelialization of
full-thickness skin wounds. In the early stages of
wound repair, transgenic mice exhibited signi®cantly
higher numbers of proliferating keratinocytes at the
wound edges and increased formation of granulation
tissue with enhanced neovascularization. As a poten-
tial mechanism of these bene®cial changes, we iden-
ti®ed the differential temporal regulation of
cytokines such as transforming growth factor-b, a
known angiogenetic factor, interferon-g, a proin-
¯ammatory cytokine, and interleukin 6, an essential
factor for reepithelialization, in transgenic mice ver-
sus controls. We propose that the bene®cial effects
observed in GM-CSF transgenics are due not only to
direct GM-CSF action but in addition to indirect
processes via the induction of secondary cytokines.
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D
isruption of the integrity of the epidermis by
wounding evokes a response involving both bio-
chemical and cellular events designed to restore a
functional epithelium over the wounded site (Clark,
1985). The initiation of wound healing involves
sequential completion of coagulation, in¯ammation, and removal
of damaged matrix components, followed by cellular proliferation
and migration, angiogenesis, matrix synthesis and deposition,
reepithelialization, and remodeling (Martin, 1997; Baker and
Leaper, 2000). Thus, wound healing involves interactions between
different cell types and matrix components as well as communica-
tion between different cell types themselves. The latter is mediated
to a great extent by cytokines, growth factors, and their respective
receptors. The impact of increased or decreased activity of some of
these signaling molecules or signal transduction components on
wound healing has been evaluated in vivo in transgenic or knockout
animals. Examples include transforming growth factor a (TGF-a),
TGF-b superfamily members, ®broblast growth factor family
members, interleukins (ILs), chemokines, and the respective
receptors (Grose and Sabine, 2001).
Very few of these proteins, e.g., platelet-derived growth factor
(Rees et al, 1999), have ever been used in clinical settings. In
contrast, granulocyte±macrophage colony stimulating factor (GM-
CSF) has been shown to exert bene®cial effects on wound healing
in patients suffering from poorly healing wounds and chronic skin
ulcers of diverse etiology, e.g., hydroxyurea-related leg ulcers
(Stagno et al, 1999), venous leg ulcers (Da Costa et al, 1999),
hemoglobinopathy-related ulcers (Voskaridou et al, 1999), and
wounds resulting from amputation (Gaches et al, 1998).
Furthermore, intradermal administration of GM-CSF to leprosy
patients with skin lesions leads to enhanced wound healing and
increased numbers and layers of keratinocytes (Kaplan et al, 1992;
Braunstein et al, 1994). There is one study, however, where no
bene®cial effects of GM-CSF application were identi®ed in
normally healing wounds (Ure et al, 1998). The bene®cial effects
of GM-CSF have been associated with increased keratinocyte
proliferation and increased breaking strength of wounds.
Upon epidermal activation such as injury or 12-O-tetradeca-
noylphorbol-13-acetate (TPA) treatment, GM-CSF mRNA
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accumulates in keratinocytes within a few hours (Robertson et al,
1994; Vasunia et al, 1994). GM-CSF is therefore an early response
gene and may evoke a series of events eventually resulting in
wound closure and tissue remodeling. GM-CSF is a potent
mitogen for keratinocytes at nanogram per milliliter concentrations
(Kawada et al, 1997) and it directly stimulates the migration and
proliferation of human endothelial cells and the growth of human
keratinocytes in vitro (Hancock et al, 1988; Bussolino et al, 1989). In
addition, it is hypothesized that GM-CSF in¯uences proliferation,
maturation, and recruitment of cells like keratinocytes, ®broblasts,
endothelial cells, monocytes, macrophages, and dendritic cells, at
least in part by modulating the release of cytokines such as IL-1,
IL-6, tumor necrosis factor a (TNF-a), TGF-b, interferon-g
(IFN-g), and M-CSF, which in turn affect the healing process
(Stagno et al, 1999).
There are animal models allowing the evaluation of
exogenously applied GM-CSF or the transient, cutaneous
expression of GM-CSF from an adenoviral vector (Jyung et al,
1994a; Xing et al, 1997a). For example, enhanced wound
healing in a surgical incision model and steroid-treated
monocyte-depleted animals by locally applied GM-CSF has
been reported (Jyung et al, 1994a). There is no animal model,
however, to evaluate (i) the consequences of long-term
cutaneous overexpression of GM-CSF, (ii) the impact of excess
keratinocyte-derived GM-CSF on wound healing, and (iii) the
mechanisms by which this cytokine alters wound healing
processes. The latter point is of exceptional interest, as GM-
CSF is known both to be produced by and to target many
different cell types involved in tissue repair including keratino-
cytes, ®broblasts, macrophages, and dendritic and endothelial
cells (Kaplan et al, 1992; Braunstein et al, 1994; Jyung et al,
1994b; Bratton et al, 1995; Caux et al, 1996).
In this study, we used previously established transgenic mice
epidermally overexpressing GM-CSF in cutaneous wound healing
studies in order to address the above-mentioned questions
(Breuhahn et al, 2000). In these transgenic mice, the wound
healing process is accelerated as demonstrated by the extent of
reepithelialization and scab rejection. At early stages of wound
repair, mitotic indices in these mice were signi®cantly higher than
in wild-type mice. In addition, signi®cantly increased neovascular-
ization of wounds was observed in GM-CSF-overexpressing mice,
which may be caused by the induction of TGF-b1 mRNA in skin
wounds of these transgenics. Besides GM-CSF and TGF-b, IL-6,
which is known to be essential for wound healing (Sano et al, 1999;
Figure 1. GM-CSF is induced in skin following TPA treatment
or wounding. (A) Skin samples were collected at different time points
after a single application of 2.5 mg TPA (n = 3 animals per experimental
time point). GM-CSF protein content in skin extracts of wild-type mice
was measured by ELISA. Strongest induction can be observed as soon as
6 h after the treatment. (B) GM-CSF protein content in skin extracts
after wounding. Transgenic mice of lines Tg1 and Tg2 as well as wild-
type littermates were wounded as described in Materials and Methods.
Four specimens were pooled for each experimental time point for
analysis. Skin extracts were prepared and GM-CSF levels were
determined by ELISA. High levels of GM-CSF during the repair process
can be observed in both transgenic lines Tg1 and Tg2, whereas the
control animals showed much lower GM-CSF tissue levels.
Figure 2. Scab rejection after wounding. At least ®ve animals of
each transgenic line, Tg1 and Tg2, as well as wild-type controls were
wounded and examined daily for scab rejection. Note the early onset of
scab rejection in both transgenic lines Tg1 and Tg2 compared to the
wild-type animals.
Figure 3. Progression of wound healing. Animals of both transgenic lines Tg1 and Tg2 as well as control animals (n > 5 animals per group and
time point) were wounded and wounds were removed and prepared for routine hematoxylin and eosin staining. (A) ±(F) Hematoxylin and eosin
stained sections from control animals (A, C, E ) and transgenic animals of line Tg2 (B, D, F); at 4 d (A, B), 6 d (C, D), and 10 d (E, F) post
wounding. Note the rapid progression of scab rejection, reepithelialization, granulation tissue formation, and tissue remodeling in transgenic animals
versus controls. (A) Arrow, arrowhead: wound margin and migrating epithelial tongue, respectively; (B±F) arrowheads: newly formed epithelium. Scale bars:
200 mm. (G) Histogram showing reepithelialization scores. Hematoxylin and eosin stained sections were evaluated in a double blinded manner for the
extent of reepithelialization, and scores ranging from I to III were allotted (I, marginal reepithelialization; II, moderate closure of wound; III, complete
closure of wound) (n = 10 wounds per group and time point). Note the early closure of wounds in transgenic animals Tg1 and Tg2 compared to the
wild-type animals.
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Figure 4. Mitotic indices during wound healing. (A)±(D) Mice were injected intraperitoneally with BrdUrd and sacri®ced after a labeling period
of 2 h (n = 10 wounds per experimental group and time point). Skin sections were stained for detection of BrdUrd-labeled S-phase nuclei. (A), (C)
Control animals; (B), (D) transgenic animals at 4 and 10 d post wounding, respectively. Four days after wounding, transgenic animals (B) exhibit more
labeled nuclei in the basal layer of the epidermis than the wild-type animals (A). By 10 d post wounding, however, these relations are reversed (C, D).
Scale bars: 200 mm. (E) Histogram showing numbers of S-phase nuclei at the wound margin. BrdUrd-labeled nuclei were counted in the thickened
wound margins and related to 100 total basal cells (n = 10 wounds per group and time point). Signi®cantly higher numbers of proliferating
keratinocytes in transgenics of lines Tg1 and Tg2 compared to the wild-type animals in unwounded skin as well as at 4 d post wounding can be seen.
Ten days after wounding, controls exhibit signi®cantly higher mitotic indices compared to the transgenic animals (*p < 0.05).
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Gallucci et al, 2000), and IFN-g were also upregulated in GM-CSF
transgenic mice. We anticipate that this transgenic mouse model
will be useful in studying bene®ts, perils, and mechanisms of
GM-CSF in normal and impaired wound healing.
MATERIALS AND METHODS
Mice Transgenic mouse lines Tg1 and Tg2 overexpressing GM-CSF
under the control of the bovine keratin 5 promoter have been described
previously (Breuhahn et al, 2000; Mann et al, 2001). Transgenic mice
were maintained as heterozygotes on an inbred FVB/N background.
Wildtype siblings were used as experimental controls. All mice were bred
and housed in the animal facility of the Johannes Gutenberg University
in Mainz.
TPA application and wounding protocol Age and sex matched
mice were shaved on the mid-dorsum 1 d prior to treatment. 2.5 mg
TPA, dissolved in 200 ml acetone, were applied on the back. Animals
were sacri®ced at different time points after the treatment and dorsal skin
was collected for cytokine analysis.
Animals aged 8±10 wk were anesthetized by avertin. The backs of the
animals were shaved and swabbed with 70% ethanol. One 5 mm
diameter full-thickness excisional wound per animal was in¯icted on the
mid-dorsum, using a biopsy punch. The wounds were left unsutured and
without dressing. Subsequently, animals were housed individually. Four
to ®ve animals were analyzed for each time point and experiments were
repeated twice.
Wound analysis The wounds were observed once every day for
infection and for the rejection of scab. Animals were euthanized at 4, 8,
6, 10, 13, and 16 d after wounding. The wound area was cleaned
carefully with 70% ethanol and the entire wound, including 4±5 mm
marginal unwounded skin, was carefully excised. The wound was
divided in two halves by a median section. One half was ®xed in neutral
buffered 4% formalin and processed for paraf®n embedding. The other
half was snap-frozen by overlaying with tissue-embedding medium
(Jung, Leica Instruments, Nussloch, Germany) and immersing it
immediately in liquid nitrogen. Tissues were stored at ±80°C until
analysis.
In addition, normal skin and wounded skin at 1, 4, 7, and 10 d post
wounding were sampled, frozen in liquid nitrogen, and stored at ±80°C
for molecular analysis. At least ®ve animals for each experimental group
were taken per time point and the experiments were repeated twice.
Histology and immunohistology Sections were mounted on slides
and stained routinely with hematoxylin and eosin. Evaluation of the
sections was done in a double blind manner by two investigators,
including a senior pathologist (PS). The wounds were evaluated for the
extent of reepithelialization. Depending upon the area covered by
keratinocytes, scores ranging from I to III (I, weak; II, moderate; III,
complete reepithelialization of the wound) were allotted to each sample.
Also, granulation tissue formation, architecture, cellularity, and
in¯ammation were evaluated.
Cryosections were cut at 5 mm thickness and processed for immunos-
taining. Treatment of samples for immunohistologic procedures and
antibodies used have been described previously (Breuhahn et al, 2000). In
this study, an antibody directed to CD31 (PECAM-1, 1:100;
Pharmingen, Germany) was used for the detection of microvessels in the
wound bed. The secondary antibody was AP-conjugated and the signal
detection was carried out using NBT/X-phosphate as a chromogenic
substrate. The sections were photographed subsequently and the extent
of microvessel formation during the repair process was determined.
Determination of mitotic indices Cell proliferation assay was carried
out by BrdUrd (5-bromo-2¢-deoxy-uridine) labeling experiments using
the In situ Cell Proliferation Kit, AP, according to the manufacturer's
instructions (Boehringer Mannheim, Mannheim, Germany). The sections
were counterstained with Mayer's hemalum solution (Merck, Darmstadt,
Germany). The number of labeled nuclei in the basal layer of the
epidermis at the wound margin was determined and related to 100 total
basal cells. Values were obtained from at least ®ve animals per
experimental group and time point.
Cytokine determination Tissue extracts were prepared from the skin
samples essentially as described previously (Breuhahn et al, 2000). Total
amount of protein was determined using Bradford reagent (Biorad,
Munich, Germany). Concentrations of GM-CSF were determined using
an enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems,
Minneapolis, MN).
Northern blot analysis Northern blot analysis was done essentially as
described previously (Breuhahn et al, 2000). The hybridization probes
were generated by polymerase chain reaction (PCR) as described
previously (Breuhahn et al, 2000) with murine spleen cDNA serving as
template and using the following primer pairs: TGF-b1: 5tgfb1 (5¢-CAT
GAA TTC CTG GCG TTA CCT TGG-3¢; position 1396±1415) and
3tgfb1 (5¢-GCT CGT GGA TCC ACT TCC AAC C-3¢; position
1786±1807; GenBank accession no. NM 011577).
RNase protection assay The ribonuclease protection assays were
carried out using RiboquantÔ Multi-Probe RNase Protection assay
system (Pharmingen, San Diego, CA). The system included an In vitro
Transcription Kit, the RPA Kit, and the Multi-Probe Template Sets
mCK-3, mCK-3b, and mAPO-2. Ribonuclease protection assays were
carried out according to the manufacturer's instructions, using pooled
total RNA from at least three animals per experimental group. Total
RNA was isolated from the wound specimens using peqGOLD RNA
Pure (Peqlab Biotechnologie, Erlangen, Germany).
The band intensities were quanti®ed using the Image Quant System
(Molecular Dynamics, Sunnyvale, CA). The band intensities of different
Figure 5. Temporal expression of IFN-g and IL-6 transcripts
during the repair process as determined by RNase protection
assay. (A) IFN-g; (B) IL-6. Mice of both transgenic lines as well as
littermate controls were wounded and total RNA was prepared (four
wounds were pooled per experimental time point). For one
representative experiment, the relative expression levels of IFN-g and
IL-6 mRNA are shown as assessed by using a phosphoimager (Molecular
Dynamics).
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mRNA species were related to the band intensities of the housekeeping
gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or the ribo-
somal protein L32.
Statistics Data are shown as means 6 SD. Statistical signi®cance in the
differences between two groups was analyzed using Student's t test and
values of p < 0.05 were considered signi®cant.
RESULTS
GM-CSF is upregulated following treatment with TPA or
wounding On the RNA level, it had been shown previously
that GM-CSF is induced in proliferating keratinocytes and that
GM-CSF is an early response factor following treatment with
tumor promoting agents (Robertson et al, 1994; Vasunia et al, 1994;
Pastore et al, 1997; Park et al, 2001). The main cell type responsible
for the GM-CSF production in these studies has been shown to be
keratinocytes. For analysis of GM-CSF induction kinetics on the
protein level in skin we determined by ELISA tissue concentrations
for this cytokine at 3, 6, 8, 12, 18, 24, 48, and 72 h post TPA
application in wild-type mice. Highest levels of GM-CSF were
measured as soon as 6 h after the treatment and declined therafter
(Fig 1A). GM-CSF levels in skin at 1, 7, and 10 d post wounding
were elevated in transgenic, GM-CSF-overexpressing mice of lines
Tg1 and Tg2 in comparison to controls (Fig 1B). The wild-type
controls showed undetectable GM-CSF levels in normal skin and
moderate GM-CSF levels following wounding.
GM-CSF transgenics exhibit accelerated scab rejection Nine
to ten animals of each line as well as littermate controls were
wounded and inspected daily for the general appearance of the
wound, presence of infection, and scab rejection. Within 24±48 h
after wounding, most of the wounds in the animals of both
transgenic lines Tg1 and Tg2 had a dry appearance and were
covered with a scab, whereas the majority of wounds from the
wild-type animals still had a glistening moist appearance and were
covered with a thin scab. Signi®cant differences were observed in
the rate of scab rejection between transgenic lines and control
animals. First scabs were rejected in lines Tg1 and Tg2 already 6 d
post wounding (Fig 2). Seven days post wounding 25% and 60% of
scabs were rejected in lines Tg1 and Tg2 compared to only 10%
scab rejection in the animals of the control group. On day 9 post
wounding, 90% of the scabs in both the transgenic lines had fallen
off, compared to 60% scab rejection in the wild-type animals.GM-
CSF overexpression enhances reepithelialization and tissue
remodeling Sections through the center of the wounds excised
at 4, 6, 8, 10, 13, and 16 d after wounding were stained with
hematoxylin and eosin and the extent and rate of reepithelialization
was evaluated. Differences were observed in the rate of
Figure 6. Extent of neovascularization
during the repair process. (A±D) Skin sections
were stained with a CD31-speci®c antibody for
detection of blood vessels (n > 5 wounds per
group and time point). Increased numbers of
blood vessels are visible in transgenic animals
compared to the wild-type animals, 4 d post
wounding (A, B). At 16 d post wounding,
however, these differences disappeared (C, WT;
D, transgenics). Scale bars: 200 mm. (E) Graphical
representation of numbers of newly formed blood
vessels in the wound bed. Stained samples were
photographed and the numbers of microvessels
per ®eld were counted. Signi®cantly higher
numbers of blood vessels are formed at days 4 and
6 after wounding in the transgenic lines Tg1 and
Tg2 compared to the wild-type controls (*p
< 0.05).
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reepithelialization between the transgenic animals and the control
wild-type animals as exempli®ed in Fig 3(A)±(F). On a
quantitative basis, both transgenic lines Tg1 and Tg2 reached
signi®cantly higher reepithelialization scores in comparison to
controls (Fig 3G). Whereas reepithelialization was complete in
mice of lines Tg1 and Tg2 at days 6 and 8 post wounding,
respectively, complete closure of the wounded area was reached in
the wild-type control group only by 13 d post wounding (Fig 3G).
Besides reepithelialization, abundant granulation tissue with a
very high cellularity was present in the wound bed in transgenics on
day 4 post wounding (Fig 3B). By contrast, comparable abundance
and cellularity of granulation tissue could be observed in the wild-
type mice only at 6 d post wounding (Fig 3C). Similarly, the
decrease in dermal cellularity was delayed in wild-type mice versus
transgenics resulting in a signi®cantly higher cellularity at 10 d post
wounding in the control group compared to the transgenic animals
(Fig 3E, F). This enhanced tissue remodeling at the later stages of
wound repair in the transgenic animals was also re¯ected by the
presence of hair follicles in the wound bed in the transgenic
animals, which were absent at this stage in controls (Fig 3E, F).
Mitotic indices are augmented in GM-CSF
transgenics Mice of transgenic lines Tg1 and Tg2 exhibit
increased mitotic indices in the interfollicular epidermis, by a factor
of approximately 2±3 compared to control mice (Breuhahn et al,
2000). Proliferation rates at the wound edge were measured by
BrdUrd labeling at 4 and 10 d after wounding as exempli®ed in
Fig 4(A)±(D). Both transgenic lines exhibit an early proliferative
burst, with maximum proliferation rates being achieved 4 d post
wounding. Signi®cantly higher numbers of proliferating basal
keratinocytes, 42% in Tg1 and 51% in Tg2 compared to 34% in the
wild-type controls, were measured on day 4 after wounding
(Fig 4A, B, E). High proliferation rates in the wild-type controls,
albeit on a lower level than the maximum proliferation rates in
transgenics, were maintained longer in comparison to transgenics.
Therefore, on day 10 after wounding, wild-type mice exhibited
higher numbers of proliferating keratinocytes compared to the
transgenic animals (Fig 4C, D, E). Thus, the strong and early burst
in keratinocyte proliferation is followed by an earlier
downregulation of proliferation in transgenics versus controls.
Proin¯ammatory cytokines are induced in GM-CSF
transgenics Expression of mRNAs of different cytokines
relevant to cutaneous in¯ammation and ®brosis was measured
using a multitemplate set RNase protection assay including TNF-
a, TNF-b, IL-6, IFN-g, IFN-b, TGF-b1, TGF-b2, TGF-b3,
MIF, LT-b, as well as housekeeping gene transcripts L32 and
GAPDH. Signi®cant differences between transgenics and controls
in the induction of mRNA for IL-6 and IFN-g were detected
during the course of the wound repair process. The inductions of
IFN-g (Fig 5A) and IL-6 (Fig 5B) were several-fold higher in
transgenic animals compared to the wild-type littermates. No
signi®cant differences in the temporal regulation of other cytokines
like M-CSF, IL-3, and TNF-a were observed (data not shown).
GM-CSF transgenics exhibit enhanced neovascularization
after wounding Sections were stained with an antibody directed
against CD31 and the extent of microvessel formation during the
repair process was determined (Fig 6A±E). CD31-positive
microvessels were counted and expressed as numbers per ®eld.
The number of newly formed capillaries was signi®cantly higher in
both transgenic lines 4 d post wounding compared to the control
group (Fig 6A, B). Transgenic mice of lines Tg1 and Tg2
exhibited 54 and 61 microvessels per vision ®eld, respectively,
compared to 42 microvessels per ®eld in the wild-type mice
(Fig 6E). After day 4 post wounding the numbers of microvessels
gradually decreased in both transgenics and the nontransgenic
controls. A faster decline in transgenics, however, leads to an
approximation of microvessel density between transgenic animals
and control animals at day 16 post wounding (Fig 6C±E).
TGF-b1 expression is differentially regulated during the
repair process As TGF-b1 has been shown to play an important
role in the process of wound healing, levels of TGF-b1 mRNA
were determined by RNase protection assay (data not shown) and
northern blot analysis (Fig 7A). The band intensities were
equalized by comparison to the band intensities for GAPDH and
a time lapse pro®le was conveyed (Fig 7B). Transgenic mice of
lines Tg1 and Tg2 exhibited two to four times higher levels of
TGF-b1 mRNA compared to control mice in unwounded skin.
During wound healing, mRNA levels of this isoform were also
elevated at least 2-fold in transgenics as well as in controls as
exempli®ed by the 10 d post wounding time point (Fig 7B).
DISCUSSION
Poorly healing and chronic wounds constitute a major challenge to
clinical care as these ailments greatly contribute to the morbidity of
patients from diverse disciplines including dermatology, oncology,
hematology, and surgery. The process of wound healing is a highly
organized event resulting in the restoration of an intact barrier
function of the skin. It involves interactions of many different cell
types, matrix components, and biochemical factors. GM-CSF is a
possible candidate for a central growth factor because it is
synthesized by a number of cellular components of the repair
process, e.g., keratinocytes, endothelial cells, ®broblasts, dendritic
cells, and macrophages (Dedhar et al, 1988; Bussolino et al, 1989,
1991; Caux et al, 1992; Braunstein et al, 1994; Breuhahn et al,
2000). In normal skin GM-CSF is not synthesized by keratinocytes
in sizeable amounts. Upregulation of GM-CSF has been shown to
be an early event after injury or treatment with a tumor promoting
Figure 7. Expression of TGF-b1 mRNA. Northern blot analysis was
performed in order to investigate the temporal regulation of TGF-b1
transcripts during the repair process. Total RNA from four to ®ve
wounds were pooled per experimental time point. Increased basal levels
of TGF-b1 mRNA were detected in Tg1 and Tg2 (A). Quantitative
evaluation of TGF-b1 expression in relation to GAPDH expression (B).
Note the higher level of TGF-b1 expression in unwounded skin of
transgenics in comparison to controls.
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agent, however (Robertson et al, 1994; Vasunia et al, 1994; Pastore
et al, 1997). Consistent with these observations, we found a strong
upregulation of GM-CSF at the protein level in murine skin shortly
after irritation. At 4 h post activation, the earliest timepoint
analyzed, signi®cant tissue levels for GM-CSF were measured. The
peak of GM-CSF tissue concentration was found around 6 h post
irritation followed by a gradual decrease over several days. Thus,
GM-CSF has to be considered an early response factor in skin
regeneration.
So far, the effects of GM-CSF in the process of wound healing
have been discussed controversially. On the one hand it has been
shown to improve healing of chronic wounds and ulcers of
different etiology (Kaplan et al, 1992; Kaplan, 1993; El Saghir et al,
1997; Jaschke et al, 1999). On the other hand, it has been reported
to have no effect on the healing process in healthy individuals (Ure
et al, 1998). In most cases, GM-CSF was applied either topically or
by perilesional injections. In this study, we have analyzed the
process of cutaneous wound healing in a transgenic mouse model
with constitutive overexpression of GM-CSF by keratinocytes in
unwounded skin (Breuhahn et al, 2000). We were able to show
that, at all stages of wound repair, GM-CSF tissue levels were
several-fold higher in transgenic animals versus controls. This model
was used to examine the effects of a continuous excess of
keratinocyte-derived GM-CSF on wound repair.
We started out to analyze the process of normal cutaneous
wound healing in these animals. Healing of full-thickness excisional
wounds as measured by the time required for scab rejection and for
the complete reepithelialization of the wounds was enhanced in
transgenic mice in comparison to the littermate controls. We
propose that there are several distinct mechanisms by which GM-
CSF accelerates wound healing in our transgenic mouse model.
(i) GM-CSF has been shown to possess positive effects on
keratinocyte growth in vitro and in vivo (Hancock et al, 1988;
Braunstein et al, 1994; Breuhahn et al, 2000). It is known to
stimulate proliferation and migration of human keratinocytes and
endothelial cells (Bussolino et al, 1989; Kawada et al, 1997). In
accordance with these ®ndings, we observed a stronger induction
of keratinocyte proliferation early after wounding in our transgenic
mice compared to control mice. This hyperproliferation in
conjunction with enhanced migratory capabilities of keratinocytes
most probably accounts for the rapid in¯ux of keratinocytes into
the wounded site in transgenics resulting in accelerated reepithe-
lialization. We attribute this hyperproliferative response in
transgenics mainly to post wounding stimuli. The activation state
of keratinocytes in the transgenic animals in the unwounded state is
low despite the observed hyperproliferation as determined by the
absence of stress marker keratin 6/16 (Breuhahn et al, 2000).
(ii) Besides reepithelialization, the in®ltration of various cell types
into the wound area and the subsequent formation of a thorough
granulation tissue is a prerequisite for successful wound repair.
Transient expression of GM-CSF using a replication-de®cient
adenoviral vector resulted in in¯ammation and massive in®ltration
of the site as well as epidermal hyperplasia (Rajagopalan et al, 1995;
Xing et al, 1997a). GM-CSF has been shown to be chemotactic for
a number of cells like Langerhans cells, macrophages, neutrophils,
®broblasts, and endothelial cells (Ruef and Coleman, 1990;
Bussolino et al, 1991; Jones, 1993; Braunstein et al, 1994; Xing et
al, 1997b). Thus, more abundant granulation tissue formation with
higher cellularity was present earlier after wounding in the
transgenic animals than in littermate controls.
(iii) Neovascularization of the wound area is pivotal for the supply
of components essential for tissue repair as well as for the disposal of
debris. GM-CSF has been shown to induce proliferation and
migration of endothelial cells (Bussolino et al, 1991). Consistent
with these ®ndings, we observed both accelerated and increased
neovascularization of the wound bed in transgenic animals versus
controls.
Although some of these actions such as autocrine stimulation
of keratinocyte proliferation can be directly brought about by
GM-CSF itself (Breuhahn et al, 2000), other effects are most
probably invoked by the GM-CSF-mediated release of other
cytokines and growth factors as demonstrated in our study for
IFN-g, IL-6, and TGF-b1. IFN-g is a central, proin¯ammatory
cytokine that has activating and chemoattractant activities on
many cell types required for granulation tissue formation
(Valente et al, 1998; Gasperini et al, 1999; Li et al, 2000).
Thus, the higher level of IFN-g expression in transgenics versus
controls may account for the accelerated and more intense
formation of granulation tissue in these animals. Likewise, the
necessity of IL-6 and activation of the STAT-3 signaling
pathway for wound healing is well established (Sano et al, 1999;
Gallucci et al, 2000). It has been shown previously that IL-6
expression is upregulated following injury (Pajulo et al, 1999). It
is produced mainly by keratinocytes, but also by macrophages,
Langerhans cells, and ®broblasts (Paquet and Pierard, 1996).
An important aspect of this study is the induction of TGF-b1
by GM-CSF. It had been shown previously that GM-CSF
overexpression in lungs of rats leads to a marked increase in
TGF-b1 protein levels in bronchioalveolar lavage ¯uids (Xing et
al, 1996; 1997b). TGF-b1 has been well documented as a
potent growth inhibitor for epithelial cells in vitro and in vivo
(Glick et al, 1993; Wang et al, 1997; Wang D et al, 1999;
Wang XJ et al, 1999). In contrast, numerous animal studies
have shown that exogenously applied TGF-b1 enhances
epidermal wound healing (Mustoe et al, 1991; Schmid et al,
1993). Initiation of a number of events essential for wound
healing such as production of cytokines and in¯ammatory
mediators, chemoattraction of monocytes and leukocytes, regu-
lation of ®broblast function, induction of angiogenesis, and
modulation of synthesis of proteases and extracellular matrix
have been attributed to TGF-b1 (Moses et al, 1990; Quaglino et
al, 1990, 1991; Salo et al, 1991; Moses, 1992; Border and
Noble, 1994).
It is notable that the acceleration of reepithelialization and
intensi®cation of granulation tissue formation does not alter the
subsequent succession of events at later stages of wound healing,
e.g., dissolution of granulation tissue, remodeling, and wound
contraction. This is also re¯ected by the downregulation of TGF-
b1 expression in transgenics versus controls at day 10 post
wounding. The more advanced stage of wound repair in these
animals corresponds to declined TGF-b1 expression levels (Frank et
al, 1996). The effect of a continuous surplus of keratinocyte-
derived GM-CSF appears to be bene®cial in normal wound
healing. The discrepancy in the one report that found no effect of
GM-CSF on normal wound healing may be explained by the
singular application of this cytokine in the underlying study (Ure et
al, 1998). Our animal model is now being used to resolve this
discrepancy.
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